Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10245146 | 0.85 | SMN1; SMN2 (0.75) | CYP1A2CYP2C19CYP3A4GAAHDAC3 | |
| SCHEMBL5163568 | 0.83 | CYP1A2 (0.60) | CYP1A2CYP2C19CYP3A4GAAHDAC3 | |
| SCHEMBL3578730 | 0.81 | HDAC3 (0.72) | CYP1A2CYP2C19CYP3A4GAAHDAC3 | |
| SCHEMBL12923812 | 0.81 | HDAC3 (0.72) | CYP1A2CYP2C19CYP3A4GAAHDAC3 | |
| SCHEMBL8330077 | 0.80 | HDAC3 (0.60) | CYP1A2CYP2C19CYP3A4GAAHDAC3 | |
| SCHEMBL7540393 | 0.78 | HDAC3 (0.57) | CYP1A2CYP2C19CYP3A4GAAHDAC3 | |
| SCHEMBL25463640 | 0.78 | HDAC3 (0.72) | CYP1A2CYP2C19CYP3A4GAAHDAC3 | |
| SCHEMBL31182037 | 0.78 | HDAC3 (0.57) | CYP1A2CYP2C19CYP3A4GAAHDAC3 | |
| SCHEMBL23984472 | 0.77 | HDAC3 (0.66) | CYP1A2CYP2C19CYP3A4GAAHDAC3 | |
| SCHEMBL15574339 | 0.77 | ALDH1A1 (0.61) | CYP1A2CYP2C19CYP3A4GAAHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023288242-A1 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-9486497-B2 | Treatment of immunocompromised conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-11-08 | — | — | US | disclosed |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
| US-9254322-B2 | Compositions comprising E-selectin antagonists and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-02-09 | — | — | US | disclosed |
| EP-2249854-B1 | TREATMENT OF IMMUNOCOMPROMISED CONDITIONS WITH E-SELECTIN ANTAGONIST AND G-CSF | MATER MEDICAL RES INST (AU) | 2015-01-21 | — | — | EP | disclosed |
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE | 2011-01-27 | — | — | US | disclosed |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE (AU) | 2011-01-06 | — | — | US | disclosed |
| US-5994270-A | CONTROLLING GAEUMANNOMYCES | MONSANTO COMPANY (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0619297-B1 | Fungicides for the control of take-all desease of plants | MONSANTO CO (US) | 1997-06-18 | — | — | EP | disclosed |
| EP-0619297-A1 | Fungicides for the control of take-all desease of plants | MONSANTO COMPANY (US) | 1994-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELL | CYP1A2 3624/4885CYP2C19 3843/4885CYP3A4 4277/4885 |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELPLG | CYP1A2 2597/4885CYP2C19 2746/4885CYP3A4 3837/4885 |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | SELL, SELP, SELE | CYP1A2 3803/4885CYP2C19 4048/4885CYP3A4 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.